| . | Plasma ionized calcium . | . | ||
|---|---|---|---|---|
| Hypocalcemia | Reference interval | Hypercalcemia | P | |
| Plasma ionized calcium, mmol/L* | 1.11 (1.10-1.12) | 1.21 (1.18-1.24) | 1.36 (1.34-1.40) | |
| n | 2564 | 101 543 | 2667 | |
| Men, n (%) | 1385 (54) | 45 842 (45) | 786 (29) | 6 × 10-72 |
| Age, years* | 55.6 (45.7-68.5) | 58.0 (48.2-67.3) | 63.6 (54.8-71.1) | 2 × 10-66 |
| Ever smokers, n (%) | 1397 (54) | 59 104 (58) | 1645 (62) | 1 × 10-7 |
| Body mass index, kg/m2* | 25.8 (23.3-28.8) | 25.6 (23.2-28.4) | 25.7 (23.2-28.7) | 0.64 |
| Alcohol consumption, g/week* | 84 (36-168) | 96 (48-180) | 108 (48-180) | 1 × 10-6 |
| High income, n (%) | 1167 (46) | 43 743 (43) | 875 (33) | 6 × 10-21 |
| High physical activity in leisure time, n (%) | 204 (8.0) | 6825 (6.7) | 132 (5.0) | 1 × 10-5 |
| Systolic blood pressure, mmHg* | 140 (126-155) | 140 (126-155) | 142 (130-157) | 2 × 10-7 |
| Diabetes, n (%) | 142 (5.5) | 4243 (4.2) | 140 (5.3) | 0.66 |
| Use of diuretics, n (%) | 277 (11) | 6911 (6.8) | 266 (10) | 0.32 |
| eGFR < 60 mL/min/1.73 m2, % | 310 (12) | 9663 (9.5) | 402 (15) | 1 × 10-4 |
| Plasma non-HDL cholesterol, mmol/L* | 3.8 (3.0-4.5) | 3.9 (3.2-4.7) | 4.0 (3.3-4.8) | 6 × 10-14 |
| Plasma vitamin D < 50nmol/L, n (%)a | 204 (41) | 10 932 (45) | 234 (43) | 0.66 |
| Antihypertensive treatment at baseline, n (%) | 542 (21) | 19 777 (20) | 761 (29) | 5 × 10-12 |
| Hypertension at baseline, n (%) | 1412 (55) | 56 294 (55) | 1642 (62) | 2 × 10-6 |
| Any use of dietary supplements, n (%) | 1128 (44) | 49 022 (48) | 1489 (56) | 7 × 10-18 |
| Other chronic disease, n (%) | 329 (13) | 10 557 (10) | 405(15) | 0..003 |
| Hyperparathyroidism diagnosis prior to baseline, n (%) | 6 (0.2) | 147 (0.1) | 50 (1.9) | 6 × 10-44 |
| Hormone replacement therapy**, n (%) | 133 (11) | 6736 (12) | 264 (14) | 0.01 |
| . | Plasma ionized calcium . | . | ||
|---|---|---|---|---|
| Hypocalcemia | Reference interval | Hypercalcemia | P | |
| Plasma ionized calcium, mmol/L* | 1.11 (1.10-1.12) | 1.21 (1.18-1.24) | 1.36 (1.34-1.40) | |
| n | 2564 | 101 543 | 2667 | |
| Men, n (%) | 1385 (54) | 45 842 (45) | 786 (29) | 6 × 10-72 |
| Age, years* | 55.6 (45.7-68.5) | 58.0 (48.2-67.3) | 63.6 (54.8-71.1) | 2 × 10-66 |
| Ever smokers, n (%) | 1397 (54) | 59 104 (58) | 1645 (62) | 1 × 10-7 |
| Body mass index, kg/m2* | 25.8 (23.3-28.8) | 25.6 (23.2-28.4) | 25.7 (23.2-28.7) | 0.64 |
| Alcohol consumption, g/week* | 84 (36-168) | 96 (48-180) | 108 (48-180) | 1 × 10-6 |
| High income, n (%) | 1167 (46) | 43 743 (43) | 875 (33) | 6 × 10-21 |
| High physical activity in leisure time, n (%) | 204 (8.0) | 6825 (6.7) | 132 (5.0) | 1 × 10-5 |
| Systolic blood pressure, mmHg* | 140 (126-155) | 140 (126-155) | 142 (130-157) | 2 × 10-7 |
| Diabetes, n (%) | 142 (5.5) | 4243 (4.2) | 140 (5.3) | 0.66 |
| Use of diuretics, n (%) | 277 (11) | 6911 (6.8) | 266 (10) | 0.32 |
| eGFR < 60 mL/min/1.73 m2, % | 310 (12) | 9663 (9.5) | 402 (15) | 1 × 10-4 |
| Plasma non-HDL cholesterol, mmol/L* | 3.8 (3.0-4.5) | 3.9 (3.2-4.7) | 4.0 (3.3-4.8) | 6 × 10-14 |
| Plasma vitamin D < 50nmol/L, n (%)a | 204 (41) | 10 932 (45) | 234 (43) | 0.66 |
| Antihypertensive treatment at baseline, n (%) | 542 (21) | 19 777 (20) | 761 (29) | 5 × 10-12 |
| Hypertension at baseline, n (%) | 1412 (55) | 56 294 (55) | 1642 (62) | 2 × 10-6 |
| Any use of dietary supplements, n (%) | 1128 (44) | 49 022 (48) | 1489 (56) | 7 × 10-18 |
| Other chronic disease, n (%) | 329 (13) | 10 557 (10) | 405(15) | 0..003 |
| Hyperparathyroidism diagnosis prior to baseline, n (%) | 6 (0.2) | 147 (0.1) | 50 (1.9) | 6 × 10-44 |
| Hormone replacement therapy**, n (%) | 133 (11) | 6736 (12) | 264 (14) | 0.01 |
* Median (interquartile range).
Only measured in a subgroup of participants.
Other chronic diseases: any diagnosis of chronic obstructive pulmonary disease, diabetes type 1 or type 2 or cancer (non-melanoma skin cancer excluded) prior to examination date.
Hormone replacement therapy is any reported use of hormone replacement therapy or use of birth control pills after menopause among women. Only reported for women. eGFR: estimated glomerular filtration rate.
| . | Plasma ionized calcium . | . | ||
|---|---|---|---|---|
| Hypocalcemia | Reference interval | Hypercalcemia | P | |
| Plasma ionized calcium, mmol/L* | 1.11 (1.10-1.12) | 1.21 (1.18-1.24) | 1.36 (1.34-1.40) | |
| n | 2564 | 101 543 | 2667 | |
| Men, n (%) | 1385 (54) | 45 842 (45) | 786 (29) | 6 × 10-72 |
| Age, years* | 55.6 (45.7-68.5) | 58.0 (48.2-67.3) | 63.6 (54.8-71.1) | 2 × 10-66 |
| Ever smokers, n (%) | 1397 (54) | 59 104 (58) | 1645 (62) | 1 × 10-7 |
| Body mass index, kg/m2* | 25.8 (23.3-28.8) | 25.6 (23.2-28.4) | 25.7 (23.2-28.7) | 0.64 |
| Alcohol consumption, g/week* | 84 (36-168) | 96 (48-180) | 108 (48-180) | 1 × 10-6 |
| High income, n (%) | 1167 (46) | 43 743 (43) | 875 (33) | 6 × 10-21 |
| High physical activity in leisure time, n (%) | 204 (8.0) | 6825 (6.7) | 132 (5.0) | 1 × 10-5 |
| Systolic blood pressure, mmHg* | 140 (126-155) | 140 (126-155) | 142 (130-157) | 2 × 10-7 |
| Diabetes, n (%) | 142 (5.5) | 4243 (4.2) | 140 (5.3) | 0.66 |
| Use of diuretics, n (%) | 277 (11) | 6911 (6.8) | 266 (10) | 0.32 |
| eGFR < 60 mL/min/1.73 m2, % | 310 (12) | 9663 (9.5) | 402 (15) | 1 × 10-4 |
| Plasma non-HDL cholesterol, mmol/L* | 3.8 (3.0-4.5) | 3.9 (3.2-4.7) | 4.0 (3.3-4.8) | 6 × 10-14 |
| Plasma vitamin D < 50nmol/L, n (%)a | 204 (41) | 10 932 (45) | 234 (43) | 0.66 |
| Antihypertensive treatment at baseline, n (%) | 542 (21) | 19 777 (20) | 761 (29) | 5 × 10-12 |
| Hypertension at baseline, n (%) | 1412 (55) | 56 294 (55) | 1642 (62) | 2 × 10-6 |
| Any use of dietary supplements, n (%) | 1128 (44) | 49 022 (48) | 1489 (56) | 7 × 10-18 |
| Other chronic disease, n (%) | 329 (13) | 10 557 (10) | 405(15) | 0..003 |
| Hyperparathyroidism diagnosis prior to baseline, n (%) | 6 (0.2) | 147 (0.1) | 50 (1.9) | 6 × 10-44 |
| Hormone replacement therapy**, n (%) | 133 (11) | 6736 (12) | 264 (14) | 0.01 |
| . | Plasma ionized calcium . | . | ||
|---|---|---|---|---|
| Hypocalcemia | Reference interval | Hypercalcemia | P | |
| Plasma ionized calcium, mmol/L* | 1.11 (1.10-1.12) | 1.21 (1.18-1.24) | 1.36 (1.34-1.40) | |
| n | 2564 | 101 543 | 2667 | |
| Men, n (%) | 1385 (54) | 45 842 (45) | 786 (29) | 6 × 10-72 |
| Age, years* | 55.6 (45.7-68.5) | 58.0 (48.2-67.3) | 63.6 (54.8-71.1) | 2 × 10-66 |
| Ever smokers, n (%) | 1397 (54) | 59 104 (58) | 1645 (62) | 1 × 10-7 |
| Body mass index, kg/m2* | 25.8 (23.3-28.8) | 25.6 (23.2-28.4) | 25.7 (23.2-28.7) | 0.64 |
| Alcohol consumption, g/week* | 84 (36-168) | 96 (48-180) | 108 (48-180) | 1 × 10-6 |
| High income, n (%) | 1167 (46) | 43 743 (43) | 875 (33) | 6 × 10-21 |
| High physical activity in leisure time, n (%) | 204 (8.0) | 6825 (6.7) | 132 (5.0) | 1 × 10-5 |
| Systolic blood pressure, mmHg* | 140 (126-155) | 140 (126-155) | 142 (130-157) | 2 × 10-7 |
| Diabetes, n (%) | 142 (5.5) | 4243 (4.2) | 140 (5.3) | 0.66 |
| Use of diuretics, n (%) | 277 (11) | 6911 (6.8) | 266 (10) | 0.32 |
| eGFR < 60 mL/min/1.73 m2, % | 310 (12) | 9663 (9.5) | 402 (15) | 1 × 10-4 |
| Plasma non-HDL cholesterol, mmol/L* | 3.8 (3.0-4.5) | 3.9 (3.2-4.7) | 4.0 (3.3-4.8) | 6 × 10-14 |
| Plasma vitamin D < 50nmol/L, n (%)a | 204 (41) | 10 932 (45) | 234 (43) | 0.66 |
| Antihypertensive treatment at baseline, n (%) | 542 (21) | 19 777 (20) | 761 (29) | 5 × 10-12 |
| Hypertension at baseline, n (%) | 1412 (55) | 56 294 (55) | 1642 (62) | 2 × 10-6 |
| Any use of dietary supplements, n (%) | 1128 (44) | 49 022 (48) | 1489 (56) | 7 × 10-18 |
| Other chronic disease, n (%) | 329 (13) | 10 557 (10) | 405(15) | 0..003 |
| Hyperparathyroidism diagnosis prior to baseline, n (%) | 6 (0.2) | 147 (0.1) | 50 (1.9) | 6 × 10-44 |
| Hormone replacement therapy**, n (%) | 133 (11) | 6736 (12) | 264 (14) | 0.01 |
* Median (interquartile range).
Only measured in a subgroup of participants.
Other chronic diseases: any diagnosis of chronic obstructive pulmonary disease, diabetes type 1 or type 2 or cancer (non-melanoma skin cancer excluded) prior to examination date.
Hormone replacement therapy is any reported use of hormone replacement therapy or use of birth control pills after menopause among women. Only reported for women. eGFR: estimated glomerular filtration rate.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
